Ocuphire Pharma, Inc. (OCUP)
| Market Cap | 130.37M |
| Revenue (ttm) | 1.15M |
| Net Income (ttm) | -6.37M |
| Shares Out | 1.06M |
| EPS (ttm) | -6.24 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 26 |
| Last Price | $12.18 |
| Previous Close | $11.73 |
| Change ($) | 0.45 |
| Change (%) | 3.84% |
| Day's Open | 11.76 |
| Day's Range | 11.51 - 12.20 |
| Day's Volume | 129,840 |
| 52-Week Range | 1.31 - 12.20 |
Durability of Nyxol's Pupil Constricting Effects Using an Evening Dosing Regimen Informs Dosing Strategy for Phase 2 Trial in Presbyopia and Phase 3 Trial in NVD
FARMINGTON HILLS, Mich., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for ...
ROCKVILLE, Md., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) (“Rexahn”) announced today that the merger transaction between Rexahn and Ocuphire Pharma, Inc. is ...
ROCKVILLE, Md., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) (“Rexahn”) announced today that at its special meeting of stockholders held on November 2, 2020, Re...
NEW YORK, June 29, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger between Rexahn Pharmaceuticals, Inc. (NASDAQ: REXN) and Ocuphir...
New York, New York--(Newsfile Corp. - June 22, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Rexahn Pharmaceuticals, Inc. (...
Transaction to Create a Nasdaq-listed Biopharmaceutical Company Focused on Advancing Ocuphire’s Late-Stage Clinical Pipeline of Ophthalmic Drug Candidates
About OCUP
Ocuphire Pharma, a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing various therapies for the treatment of various eye disorders. The company's pipeline includes small-molecule product candidates for front and back of the eye indications. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate to reduce pupil size that is entering into Phase 3 clinical development for dim light or night vision disturbances, and reversal pharmacologi... [Read more...]
| Industry Biotechnology | |
| CEO Douglas Swirsky | Country United States |
| Stock Exchange NASDAQ | Ticker Symbol OCUP |
Analyst Forecasts
The average 12-month stock price forecast for OCUP is 15.00, which is an increase of 23.15% from the latest price.